Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study of PGN EDODM1 for myotonic dystrophy type 1

X
Trial Profile

A Clinical Study of PGN EDODM1 for myotonic dystrophy type 1

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PGN-EDODM1 (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions; First in man
  • Acronyms FREEDOM-EDODM1
  • Sponsors Pepgen Corporation
  • Most Recent Events

    • 08 Aug 2023 According to a Pepgen Corporation media release, the company continue to pursue global strategy of initiating FREEDOM-EDODM1 clinical study in geographies outside the U.S
    • 13 Jun 2023 According to a Pepgen Corporation media release, the company awaits receipt of an official clinical hold letter from US FDA and withdraw its prior guidance with respect to the timeline for initiating trial in first half of 2023.
    • 30 May 2023 Status changed from planning to suspended, according to a Pepgen Corporation media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top